Peptides Are Everywhere—So It’s Time for a Serious Conversation

Why FDA and Pharmacy Regulators Should Keep the Door Open

Peptides are in a strange spot right now.

They’re everywhere: talked about in clinical circles, quietly incorporated into certain care plans, marketed aggressively online, and actively sought by patients looking for legitimate therapeutic benefits. Yet at the same time, pharmacies largely remain on the sidelines, regulatory pathways are limited or unclear, and the category is often treated as something regulators would rather avoid than evaluate.

That tension is understandable. But it’s also uncomfortable and worth a closer look. Because peptides aren’t some fringe wellness invention or synthetic novelty. They’re part of how the human body works.

Insulin is a peptide hormone. So are glucagon, oxytocin, vasopressin, corticotropin, and countless other hormones, enzymes, and signaling molecules that regulate metabolism, inflammation, healing, and communication at the cellular level. Put simply, peptides aren’t foreign to human biology. They are human biology. And that alone suggests the current regulatory posture deserves more discussion than it’s getting.

The Regulatory Reality Is Structural

Let’s be clear about where things stand today.

Under existing federal and state frameworks, most peptides do not fit neatly into established pathways for routine pharmacy involvement. They are not approved as drugs by the FDA, they often do not appear on permissible bulk substance lists, and they frequently surface in commerce under the label of research use only, even when real-world patient use is obvious.

From a compliance standpoint, pharmacies are right to be cautious. The risk is real, and the boundaries are not ambiguous. But it’s important to understand why those boundaries exist.

This isn’t because the FDA or state boards have made a categorical determination that peptides are unsafe, ineffective, or inappropriate across the board. In most cases, it’s because the regulatory framework has not yet caught up with the science, the clinical experimentation, or the sustained patient demand. That distinction matters.

When illegality is rooted in regulatory absence rather than scientific rejection, history suggests frameworks eventually follow, if regulators are willing to engage.

Acknowledging What We Don’t Yet Know

None of this is to suggest that peptides are risk-free or fully understood. Some peptides have been studied extensively; others have not. Long-term safety data are uneven. Dosing, sourcing, and formulation matter. And there may well be substances currently marketed as peptides that should never find their way into patient care. That uncertainty should not be ignored. But uncertainty should not end the conversation either.

If anything, it should invite more oversight, more structure, and more professional involvement, not silence. Patients are already using peptides today, often without the safeguards that come with regulated manufacturing, dispensing, and pharmacist oversight. The real choice facing regulators isn’t whether peptides will be used. They already are. The choice is whether that use happens in fragmented, opaque markets or within systems designed to protect patients.

Demand Is Real and Persistent

Patients are seeking peptides for weight management, metabolic disease, inflammatory conditions, muscle preservation, wound healing, and hormone-related disorders. Some clinicians approach this cautiously. Others do not. But the demand continues despite legal ambiguity, not because of it.

When demand exists at scale, enforcement alone rarely resolves the issue. Instead, it pushes activity into less transparent channels: offshore suppliers, influencer-backed brands, and legal loopholes that offer little accountability.

Pharmacies Are Not the Weak Link

If the FDA and state boards ever take a serious, forward look at peptides, pharmacies should sit at the center of that conversation.

Not because pharmacies want special treatment, but because pharmacies bring exactly what the current peptide marketplace lacks:

• Controlled sourcing and quality standards
• Pharmacist oversight and professional judgment
• Documentation, traceability, and inspection
• Clear lines of accountability between prescriber, dispenser, and patient

If patient safety is the goal—and it should be—licensed pharmacies are not the risk. They are the infrastructure. Wellness spas, social media brands, overseas suppliers, and research chemical labels dominate this space largely because regulated pathways do not exist.

The FDA Has Been Here Before

This would not be new territory for the FDA. Biologics, biosimilars, complex injectables, sterile compounding oversight, and even cell-based therapies once lived in regulatory gray zones. Each raised safety questions. Each required careful study. In time, the FDA engaged, evaluated the risks, and built structure around them. Peptides deserve the same level of seriousness.

What Pharmacies Should Do Now

For pharmacies, the message is not to operate in the shadows. The message is to stay compliant, understand the science, and monitor the regulatory and marketplace signals. Pay attention to enforcement trends. Engage thoughtfully in policy discussions. Be prepared to participate responsibly if and when lawful pathways emerge.

The Bottom Line

Peptides are already embedded in patient care. That reality should prompt thoughtful discussion, not closed doors. The FDA and state boards are uniquely positioned to bring clarity and safety to a category that sits at the intersection of biology, demand, and innovation. A measured, science-driven regulatory approach would allow real questions about safety, efficacy, and appropriate use to be addressed openly, rather than left to unregulated markets. The question isn’t whether peptides belong in health care. They already do. The real question is whether regulators and pharmacies will help shape that reality or continue reacting to it.

Ned Milenkovich, PharmD, JD, is chair of the health care law practice at Much Shelist PC and is a former vice chairman of the Illinois State Board of Pharmacy.